China Stroke Primary Prevention Trial: Visit-to-Visit Systolic Blood Pressure Variability Is an Independent Predictor of Primary Stroke in Hypertensive Patients

Xi Men, Wei Sun, Fangfang Fan, Min Zhao, Xiao Huang, Yu Wang, Lishun Liu, Ran Liu, Weiping Sun, Qing Peng, Xianhui Qin, Genfu Tang, Jianping Li, Yan Zhang, Yefeng Cai, Fan Fan Hou, Binyan Wang, Xiping Xu, Xiaoshu Cheng, Ningling Sun, Yining Huang, Yong Huo, Xi Men, Wei Sun, Fangfang Fan, Min Zhao, Xiao Huang, Yu Wang, Lishun Liu, Ran Liu, Weiping Sun, Qing Peng, Xianhui Qin, Genfu Tang, Jianping Li, Yan Zhang, Yefeng Cai, Fan Fan Hou, Binyan Wang, Xiping Xu, Xiaoshu Cheng, Ningling Sun, Yining Huang, Yong Huo

Abstract

Background: The optimal range of blood pressure variability remains unclear. We aimed to stratify the degree of risk of stroke based on visit-to-visit systolic blood pressure (SBP) variability in a large Chinese hypertensive population in 32 communities.

Methods and results: We retrospectively analyzed the data of 20 702 hypertensive patients from the China Stroke Primary Prevention Trial. The participants were randomized into 2 treatment groups to receive either enalapril or enalapril plus folic acid. Their blood pressures were measured every 3 months. The outcome was the first stroke. Three parameters of SBP variability were calculated: standard deviation, coefficient of variation, and average real variability. The records of first 4, 6, 8, 10 and 12 visits at which SBP was measured were used to calculate SBP variability and to predict subsequent stroke risk in adjusted Cox regression models. After median follow-up of 4.5 years, 597 patients had experienced stroke. Visit-to-visit SBP variability was an independent predictor of subsequent stroke (eg, the hazard ratio for the highest quintile of average real variability [22.67-61.07 mm Hg] over 6 visits was 1.55, 95% CI 1.07-2.25, P=0.021), independent of mean SBP over the follow-up period. Its value was more predictive when more blood pressure records were used.

Conclusions: Visit-to-visit SBP variability is an independent predictor of primary stroke in Chinese hypertensive patients. This predictive value depends on the number of blood pressure measurements used to calculate variability but is independent of mean SBP.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00794885.

Keywords: hypertension; stroke; systolic blood pressure variability.

© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

Figures

Figure 1
Figure 1
Flow of participants in the analysis of BPV over 6 visits. BPV indicates blood pressure variability; CSPPT, China Stroke Primary Prevention Trial.
Figure 2
Figure 2
Hazard ratios for risk of subsequent stroke by quintiles of visit‐to‐visit systolic blood pressure standard deviation, coefficient of variation and average real variability over 6 visits, with the first quintile (Q1) as the reference. The hazard ratios (95% CI) for risks of subsequent stroke in a crude model by quintiles of visit‐to‐visit systolic blood pressure variability parameters over the first 6 visits. A, Standard deviation. B, Coefficient of variation. C, Average real variability. The first quintile of each parameter is the reference category. Numbers of subsequent stroke events by quintiles are given in Table S10; Q1 to Q5, each quintile of the same parameters.

References

    1. Rafael L, Mohsen N, Kyle F, Stephen L, Kenji S, Victor A, Jerry A, Timothy A, Rakesh A, Ahn SY. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–2196.
    1. Lloyd‐Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2011;123:e18–e209.
    1. Charles W, Cathie S, Martin D, Joanna W, Peter S. Stroke. Lancet. 2003;362:1211–1224.
    1. Lawes CMM, Hoorn SV, Rodgers A; For the International Society of Hypertension . Global burden of blood‐pressure‐related disease, 2001. Lancet. 2008;371:1513–1518.
    1. WHO document . A global brief on hypertension. 2015. Available at . Accessed December 23, 2016.
    1. Liu LS. 2010 Chinese guidelines for the management of hypertension. Chin J Hypertens. 2011;39:579–615.
    1. Chobanian A; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee . Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–1252.
    1. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005;23:697–701.
    1. Parati G, Stergiou GS, Asmar R, Bilo G, De LP, Imai Y, Kario K, Lurbe E, Manolis A, Mengden T. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008;26:1505–1530.
    1. Leenen FH. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome. Can J Cardiol. 2004;20(suppl B):77B–82B.
    1. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta‐analysis of randomised trials. BMJ. 2008;336:1121–1123.
    1. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet. 2008;371:2219–2221.
    1. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit‐to‐visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895–905.
    1. Tom M. When measurements are misleading: modelling the effects of blood pressure misclassification in the English population. BMJ. 2004;328:933.
    1. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Gutnikov SA, Edwards P, Mant D, Sackley CM. Change in stroke incidence, mortality, case‐fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363:1925–1933.
    1. Yong H, Jianping L, Xianhui Q, Yining H, Xiaobin W, Gottesman RF, Genfu T, Binyan W, Dafang C, Mingli H. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in china: the CSPPT randomized clinical trial. JAMA. 2015;313:1325–1335.
    1. Bruce A, Brian MC, Stephen D, Barbara D, Laura H, Marc J, Larry M, Albert R, Julia S, Elaine U. Recommendations for blood pressure measurement in human and experimental animals; part 1: blood pressure measurement in humans. Hypertension. 2006;48:e3.
    1. Paul M, Cara J, Levitan EB, Elizabeth H, Daichi S, Webber LS, Suzanne O, Richard R, Marie KW. Reproducibility of visit‐to‐visit variability of blood pressure measured as part of routine clinical care. J Hypertens. 2011;29:2332–2338.
    1. Diaz KM, Tanner RM, Louise F, Levitan EB, Kristi R, Daichi S, Paul M. Visit‐to‐visit variability of blood pressure and cardiovascular disease and all‐cause mortality: a systematic review and meta‐analysis. Hypertension. 2014;64:965–982.
    1. Lau KK, Wong YK, Chan YH, Teo KC, Chan KH, Li LSW, Cheung RTF, Siu CW, Shu LH, Tse HF. Visit‐to‐visit blood pressure variability as a prognostic marker in patients with cardiovascular and cerebrovascular diseases—relationships and comparisons with vascular markers of atherosclerosis. Atherosclerosis. 2014;235:230–235.
    1. Paolo P, Stevo J. The role of cardiac autonomic function in hypertension and cardiovascular disease. Curr Hypertens Rep. 2009;11:199–205.
    1. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS. Effects of β blockers and calcium‐channel blockers on within‐individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469–480.
    1. Krakoff LR. Fluctuation: does blood pressure variability matter? Circulation. 2012;126:525–527.
    1. Wenhong L, Ran L, Wei S, Qing P, Weiwei Z, En X, Yan C, Meiping D, Yansheng L, Zhen H. Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions. Stroke. 2012;43:2916–2922.
    1. Briant LJB, Charkoudian N, Hart EC. Sympathetic regulation of blood pressure in normotension and hypertension: when sex matters. Exp Physiol. 2015;101:219–229.
    1. Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O'Rourke MF. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation. 1983;68:50–58.
    1. Okada H, Fukui M, Tanaka M, Matsumoto S, Mineoka Y, Nakanishi N, Asano M, Yamazaki M, Hasegawa G, Nakamura N. Visit‐to‐visit blood pressure variability is a novel risk factor for the development and progression of diabetic nephropathy in patients with type 2 diabetes. Diabetes Care. 2013;36:1908–1912.
    1. Kei A, Masahiro K, Rudolph S, Lutgarde T, Miki H, Michihiro S, Azusa H, Taku O, Ryusuke I, Hirohito M. Home blood pressure variability as cardiovascular risk factor in the population of Ohasama. Hypertension. 2012;61:61–69.
    1. Chenhui T, Yuxi S, Neng D, Dachun X, Wei C, Jiguang W, Athanase P, Van Sloten TT, Jacques B, Safar ME. Prognostic significance of visit‐to‐visit systolic blood pressure variability: a meta‐analysis of 77,299 patients. J Clin Hypertens. 2015;17:107–115 (109).
    1. Levitan EB, Niko K, Suzanne O, Stevo J, Paul M. Blood pressure measurement device, number and timing of visits, and intra‐individual visit‐to‐visit variability of blood pressure. J Clin Hypertens. 2012;14:744–750.
    1. Tully PJ, Debette S, Dartigues J‐F, Helmer C, Artero S, Tzourio C. Antihypertensive drug use, blood pressure variability, and incident stroke risk in older adults. Stroke. 2016;47:1194–1200.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner